GMP Inspections Still A Risky Process For OTC Firms – Attorney
This article was originally published in The Tan Sheet
Executive Summary
FDA's cGMP regulation revisions reflect the agency's increasing focus on compliance for OTC manufacturers, according to Scott Bass of the Washington, D.C. law firm Sidley, Austin, Brown & Wood